Cancer gene therapy

"We are evaluating the use of monoclonal antibodies (MAbs) with immunomodulatory properties for cancer treatment."


The Cancer Gene Therapy Group focuses its research on the development of alphavirus-derived self-replicating RNA-based vectors to express immunostimulatory molecules locally in tumors. These vectors have advantages such as high expression levels, induction of type I interferon (IFN) responses and apoptosis, as well as a high degree of biosafety, since they do not spread.

Cancer immunotherapy using immunomodulatory antibodies such as those directed against immune checkpoints has achieved unprecedented efficacy in the treatment of many types of tumors. However, these antibodies frequently generate toxic effects, something that also happens with cytokines with antitumor properties.

Local expression of these molecules with transient expression vectors based on self-replicating RNA (saRNA, from "self-amplifying RNA") is therefore a promising strategy.

The rise of mRNA vaccines suggests that the future lies in the delivery of these vectors in the form of RNA, for which it is necessary to develop more efficient delivery strategies.

Need more information?

If you are interested in learning more about our research, please contact us 

Objectives of the Cancer Gene Therapy
Research Group

Development of saRNA vectors expressing immunomodulatory nanobodies, immunocytokines and molecules inhibiting tumor cell adhesion and migration.

Development of non-viral vectors capable of efficiently transferring saRNA to tumors using lipid nanoparticles, cationic polymers or electroporation.

Development of new strategies to transfer DNA to tumors, including DNA capable of transcribing saRNA.

Meet the research team

Actividad científica del Grupo de Investigación de
Terapia Génica para Cáncer